Women with ER-positive
breast Ca may soon extend
tamoxifen therapy to 10 years

A new study confirms that 10 years of tamoxifen significantly lowers the breast cancer mortality rate during the second decade after diagnosis, compared with 5 years of therapy

Senior Editor

Women who have hormone-sensitive breast cancer and who have taken tamoxifen for 5 years as adjuvant therapy stand to benefit from an additional 5 years of the drug, according to preliminary findings from the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial.¹